Cisplatin resistance and oncogenes - A review

Anti-Cancer Drugs

Volumn 11, Issue 4, 2000, Pages 225-236

  Dempke, Wolfram ^a   Voigt, Wieland ^a   Grothey, Axel ^a   Hill, Bridget T ^b   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Apoptosis; Cisplatin resistance; Gene therapy; Oncogenes; Resistance modifiers

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CISPLATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLINE; DNA; DNA DIRECTED DNA POLYMERASE BETA; DNA POLYMERASE; HIGH MOBILITY GROUP PROTEIN; METALLOTHIONEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN P53; RIBOZYME; SOMATOMEDIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; BASE MISPAIRING; CANCER; DNA REPAIR; DRUG DNA BINDING; DRUG RESISTANCE; DRUG UPTAKE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE C FOS; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CISPLATIN; CYCLINS; DNA ADDUCTS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; ONCOGENES;

EID: 0034083735     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200004000-00001     Document Type: Review

References (125)

1. 1. Loehrer PJ, Einhorn LH. Cisplatin. Ann Intern Med 1984; 100: 704-13.
2. 2. Timmer-Bosscha H, Mulder NH, de Vries EGE. Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 1992; 66: 227-38.
3. 3. Chao CC. Molecular basis of cis-diamminedichloroplatinum(II) resistance: a review. J Formos Med Ass 1996; 95: 893-900.
4. 4. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-42.
5. 5. Barbacid M. Ras genes. Annu Rev Biochem 1987; 56: 779-827.
6. 6. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 1999; 17: 1071-9.
7. 7. Bokoch GM, Der CJ. Emerging concepts in the ras superfamily of GTP-binding proteins. FASEB J 1993; 7: 750-9.
8. 8. Matsuda S, Gotoh Y, Nishida E. Signaling pathways mediated by the mitogen-activated protein (MAP) kinase kinase/MAP kinase cascade. J Leuk Biol 1994; 56: 548-53.
9. 9. Heimbrook DC, Oliff A. Therapeutic intervention and signaling. Curr Opin Cell Biol 1998; 10: 284-8.
10. 10. Milne DM, Campbell DG, Caudwell FB, Meek DW. Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J Biol Chem 1994; 269: 9253-9.
11. 11. Dempke W, Voigt W, Grothey A, Schmoll HJ. Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. Anti-Cancer Drugs 1999; 10: 545-9.
12. 12. Sklar MD. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 1988; 48: 797-7.
13. 13. Isonishi S, Horn DK, Eastman A, Howell SB. Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoylphorbol-13-acetate in a human ovarian carcinoma cell line. Br J Cancer 1994; 69: 217-21.
14. 14. Niimi S, Nakagawa K, Yokota J, et al. Resistance to anticancer drugs in NIH 3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 1991; 63: 237-41.
15. 15. Levy E, Baroche C, Barret JM, et al. Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair. Carcinogenesis 1994; 15: 845-50.
16. 16. Shinohara N, Ogiso Y, Arai T, et al. Differential Na(+),K(+)-ATPase activity and cisplatin sensitivity between transformants induced by H-ras and those induced by K-ras. Int J Cancer 1994; 58: 672-7.
17. 195mPt-radiolabeled cis-diamminedichloroplatinum (II) of SHOK cells transfected with various oncogenes. Radiat Med 1998; 16: 233-7.
18. 18. Fan J, Banerjee D, Stambrook PJ, Bertino JR. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras. Biochem Pharmacol 1997; 53 1203-9.
19. 19. Perez JM, Quiroga AG, Montero EI, Alonso C, Navarro-Ranninger C. A cycloplatinated compound of p-isopropylbenzaldehyde thiosemicarbazone and its chlorobridged derivative induce apoptosis in cis-DDP resistant cells which overexpress the H-ras oncogene. J Inorg Biochem 1999; 73: 235-43.
20. 20. Perez RP, Hamaguchi K, Tracey PA, Handel LM, Hamilton TC, Godwin AK. Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity. Cancer Res 1993; 53: 3771-5.
21. 21. Holford J, Rogers P, Kelland LR. Ras mutation and platinum resistance in human ovarian carcinomas in vitro. Int J Cancer 1998; 77: 94-100.
22. 22. Kaufmann SH, Kalemkerian GP, Jasti R, Mabry M. Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin. Biochem Pharmacol 1995; 50: 1987-93.
23. 23. Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int J Cancer 1999; 80: 731-7.
24. 24. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 1994; 77: 175-8.
25. 25. Fokstuen T, Rabo YB, Zhou JN, et al. The ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line. Anticancer Res 1997; 17: 2347-52.
26. 26. Potapova O, Haghighi A, Bost F. The jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997; 272: 14041-4.
27. 27. Kaina B, Haas S, Kappes H. A general role for c-fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. Cancer Res 1997; 57: 2721-31.
28. 28. Angel P, Bhattari K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product jun/ AP-1. Cell 1988; 55: 875-85.
29. 29. Abate C, Luk D, Curran T. Transcriptional regulation by fos and jun in vitro: interaction among multiple activator and regulatory domains. Mol Cell Biol 1991; 11: 3624-32.
30. 30. Rubin E, Kharbanda S, Gunji H, Weichselbaum R, Kufe D. Cis-diaminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res 1992; 52: 878-82.
31. 31. McDonnell SE, Kerr LD, Matrissian LM. Epidermal growth factor stimulation of stromelysin mRNA in rat fibroblasts requires induction of proto-oncogenes c-fos and c-jun and activation of protein kinase C. Mol Cell Biol 1990; 10: 4284-93.
32. 32. Leirdal M, Sioud M. Ribozyme inhibition of the protein kinase Cα triggers apoptosis in glioma cells. Br J Cancer 1999; 80: 1558-64.
33. 33. Scanlon KJ, Jiao L, Funato T, et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothione. Proc Natl Acad Sci USA 1991; 88: 10591-5.
34. 34. Kovary K, Bravo R. The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol 1991; 11: 4466-72.
35. 35. Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA. Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. Mol Cell Biol 1993; 13: 841-51.
36. 36. Jenuwein T, Müller D, Curran T, Müller R. Extended life span and tumorigenicity of nonestablished mouse connective tissue cells transformed by fos oncogene of FBR-MuSV. Cell 1985; 41: 629-37.
37. 37. Smeyne RJ, Vendrell M, Hayward M, et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature 1993; 363: 166-9.
38. 38. Fritz G, Kaina B. Phosphorylation of the DNA repair protein APE/REF-1 by CKII affects redox regulation of AP-1. Oncogene 1999; 18: 1033-40.
39. 39. Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 1998; 12: 462-72.
40. 40. Kashani-Sabet M, Wang W, Scanlon KJ. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 1990; 265: 11285-8.
41. 41. Funato T, Yoshida E, Jiao L, Tone T, Kashani.Sabet M, Scanlon KJ. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv Enz Reg 1992; 32: 195-209.
42. 42. Funato T, Ishii T, Kanbe M, Scanlon KJ, Sasaki T. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme. In Vivo 1997; 11: 217-20.
43. 43. Scanlon KJ, Weizhan W, Han H. Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. Cancer Treat Rev (Suppl A) 1990; 17: 27-35.
44. 44. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers. Pharmacol Ther 1991; 52: 385-406.
45. 45. Pan B, Yao KS, Dean N, Hamilton TC, O'Dwyer PJ. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide. Proc Am Ass Cancer Res 1998: 39: 158.
46. 46. Haas S, Kaina B. c-Fos is involved in the cellular defense against the genotoxic effect of UV radiation. Carcinogenesis 1995; 16: 985-91.
47. 47. Hai T, Curran T. Cross-family dimerization of transcription factors fos/jun and ATF/CREB alters DNA specificity. Proc Natl Acad Sci USA 1991; 88: 3720-3724.
48. 48. Englander EW, Widen SG, Wilson SH. Mammalian β-polymerase promotor: phosphorylation of ATF/CRE-binding protein and regulation of DNA binding. Nucleic Acid Res 1991; 19: 3369-75.
49. 49. Cvijic ME, Chin KV. Characterization of a cAMP-dependent protein kinase mutant to cisplatin. Int J Cancer 1997; 72: 345-50.
50. 50. Cvijic ME, Yang WL, Chin KV. Cisplatin resistance in cyclic AMP-dependent protein kinase mutants. Pharmacol Ther 1998; 78: 115-28.
51. 51. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Genet Dev 1993; 3: 44-55.
52. 52. Amati B, Land H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev 1994; 4: 102-9.
53. 53. Takimoto M, Quinn JP, Farina AR, Staudt LM, Levens D. fos/jun and octamer-binding protein interact with a common site in a negative element of the human c-myc gene. J Biol Chem 1989; 264: 8992-9.
54. 54. Warenius HM, Seabra LA, Maw P. Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but no c-raf-1 protein. Int J Cancer 1998; 67: 224-31.
55. 55. Sklar MD, Prochownik EV. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res 1991; 51: 2118-23.
56. 56. Van Waardenburg RC, Prins J, Meijer C, Uges DR, De Vries EG, Mulder NH. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res 1996; 16: 1963-70.
57. 57. Mizushima Y, Kashii T, Kobayashi M. Effect of cisplatin exposure on the degree of N-myc amplification in small cell lung carcinoma cell lines with N-myc amplification. Oncology 1996; 53: 417-21.
58. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-55.
59. 59. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins, and hyperthermia. Biochem Pharmacol 1990: 40: 2353-62.
60. 60. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990; 2: 275-80.
61. 61. Evans DE, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res 1993; 53: 2133-9.
62. 62. Kastan MB, Onyekwere O, Sidrasky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
63. 63. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307-18.
64. 64. El Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
65. 1 arrest and apoptosis. Cancer Res 1994; 54: 1169-74.
66. 66. Kawasaki T, Tomita T, Bilim V, et al. Abrogation of apoptosis induced by DNA-damaging agents in human bladder cancer cell lines with p21/WAF1/CIP1 and/or P53 gene alterations. Int J Cancer 1996; 68: 501-5.
67. 67. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ. p21Waf1/Cip1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997; 14: 9229-35.
68. 68. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-54.
69. 69. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. The interaction of Rb with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 1992; 6: 177-82.
70. 70. Zamanian M, La Thangue NB. Adenovirus E1A prevents the retionblastoma gene product from repressing the activity of a cellular transcription factor. EMBO J 1992; 11: 2603-9.
71. 2-checkpoint inhibitor. Clin Cancer Res 1997; 2: 791-7.
72. 72. Gallagher WM, Cairney M, Schott B, Roninson IB, Brown R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 1997; 14: 185-93.
73. 73. Kern MA, Helmbach H, Artuc M, Karmann D, Jurgovsky K, Schadendorf D. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustin, vindesin or etoposide: modulation of proto-oncogene expression. Anticancer Res 1997; 17: 4359-70.
74. 74. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-57.
75. 75. Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995; 11: 1217-28.
76. 76. Lenz HJ, Hayashi K, Salonga D, et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998; 4: 1243-50.
77. 77. Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W, Schauer A. Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer 1998; 34: 845-50.
78. 78. Perego P, Romanelli S, Carenini N, et al. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to taxol. Ann Oncol 1998; 9: 423-30.
79. 79. Miyashita T, Krajewski S, Krajewska M. Tumor suppressor p53 is a regulator of the bcl-2 and box gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805.
80. 80. Wickremasinghe RG, Hoffbrand AV. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood 1999; 93: 3587-600.
81. L can differentially block chemotherapy-induced cell death. Blood 1997; 90: 1208-16.
82. 82. Dole M, Nunez G. Merchant AK. bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994; 54: 3253-9.
83. 83. Perego P, Giola M, Righetti SC. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-62.
84. 84. Fajac A, DaSilva J, Ahomadegbe JC. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 1996; 68: 67-74.
85. 85. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IFG-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997; 1332: 105-26.
86. 86. D'Mello SR, Galli C, Ciotti T, Calissano P. Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc Natl Acad Sci USA 1993; 90: 10989-93.
87. 87. Villa P, Kaufmann SH, Earnshaw WC. Caspases and caspases inhibitors. Trends Biochem Sci 1997; 22: 388-93.
88. L protein by caspase-3-like proteases. Oncogene 1998; 17: 1295-304.
89. 89. Suzuki M, Yagi. Stereochemical basis of DNA bending transcription factors. Nucleic Add Res 1995; 23: 2083-91.
90. 90. Ohlsson C, Kley N, Werner H, LeRoith D. p53 regulates insulin-like growth factor-I (IGF-1) receptor expression and IGF-I-induced tyrosine phosphorylatlon in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 1998; 139: 1101-7.
91. 91. Grothey A, Voigt W, Schoeber C, Mueller T, Dempke W, Schmoll HJ. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance. J Cancer Res Clin Oncol 1999; 125: 166-73.
92. 92. Eichholtz-Wirth H, Stoetzer O, Marx K. Reduced expression of the ICE-related protease CPP32 is associated with radiation-induced cisplatin resistance in HeLa cells. Br J Cancer 1997; 76: 1322-7.
93. 93. Eichholtz-Wirth H, Marx K. Clonal variability of radiation-induced cisplatin resistant HeLa cells. Anticancer Res 1998; 18: 2989-91.
94. 94. Lage H, Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 1999; 125: 156-65.
95. 95. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996; 56: 1374-81.
96. 96. Scherer SJ, Welter C, Zang KD, Dooley S. Specific in vitro binding of p53 to the promotor region of the human mismatch repair gene hMSH2. Biochem Biophys Res Comm 1996; 221: 722-8.
97. 97. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-90.
98. 98. Drummond JT, Anthoney A, Brown A, Modrich P. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumour cell line. J Biol Chem 1996; 271: 19645-8.
99. 99. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6.
100. 100. Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997; 57: 1841-5.
101. 101. Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45-52.
102. 102. Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998; 58: 3579-85.
103. 6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 1999; 80: 744-50.
104. 104. Brimmell M, Mendiola R, Mangion J, Packham G. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998; 16: 1803-12.
105. 105. Colella G, Vikhanskaya F, Codegoni AM, Bonazzi C, D'Incalci M, Broggini M. hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. Carcinogenesis 1998; 19: 691-4.
106. 2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 1997; 57: 3253-7.
107. 107. Jayaraman L, Murthy KGK, Zhu C, Curran T, Xanthoudiakis S, Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 1997; 11: 558-70.
108. 108. Wunderlich V, Bottger M. High-mobility-group proteins and cancer - an emerging link. J Cancer Res Clin Oncol 1997; 123: 133-40.
109. 109. Huang J, Logsdon N, Schmieg FI, Simmons DT. p53-mediated transcription induces resistance of DNA to UV inactivation. Oncogene 1998; 17: 401-11.
110. 110. Ho PT, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997; 24: 187-202.
111. 111. Shitara T, Scanlon KJ. Suppresion of the human carcinoma phenotype by an antioncogene ribozyme. In: Robbins PD, ed. Gene therapy protocols.. Totowa: Humana Press 1997: 391-401.
112. 112. Dean NM, McKay RA, Holmlund J. Antisense oligonucleotides as inhibitors of genes that regulate AP-1: pharmacology and clinical development. Antisense Nucleic Acids Drug Dev 1998; 8: 147-51.
113. 113. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin. Br J Cancer 1998; 78: 1035-42.
114. 114. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligodeoxynucleotide. Cancer 1994; 74: 2546-54.
115. 115. Citro G, D'Agnano I, Leonetti C, et al. c-myc-Antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998; 58: 283-9.
116. 116. Del Bufalo D, Cucco C, Leonetti C, et al. Effect of cisplatin and c-myb antisense phosphorothioate oligideoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br J Cancer 1996; 74: 387-93.
117. 117. Symons RS. Small catalytic RNAs. Annu Rev Biochem 1992; 61: 641-71.
118. 118. Song K, Li Z, Cowan KH, Sinha BK. Sensitization of cis-platinum by recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Oncol Res 1997; 9: 603-9.
119. 119. Roth JA. Gene replacement strategies for lung cancer. Curr Opin Oncol 1998; 10: 127-32.
120. 120. Basu A, Teicher BA, Lazo JS. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem 1990; 265: 8451-7.
121. 121. Hofmann J, Fiebig HH, Winterhalter BR, Berger DP, Grunicke H. Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int J Cancer 1990; 45: 536-9.
122. 122. Mann SC, Andrews PA, Howell SB. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 1991; 48: 866-72.
123. 123. Pollack IF, Kawecki S, Lazo JS. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase inhibitor. J Neurosurg 1996; 84: 1024-32.
124. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip/WAF/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997; 57: 1495-501.
125. 125. Mack PC, Edelman MJ, Gandara DR, Gumerlock. Association of RB status with activity of combination 7-hydroxy-staurosporine (UCN-01) plus cisplatin (CDDP) treatment in non-small cell lung carcinoma (NSCLC) cell lines. Proc Am Ass Cancer Res 1998; 39: 178.